Oncologists were one of the few provider groups to register support for the FDA rule, reflecting the challenge of assessing ...

The company's next-generation sequencing-based test is used to aid the detection of cancers in patients with indeterminate lesions.

The UK government said that it plans this year to repeal regulations specific to COVID-19 tests as part of the alignment with EU Common Specifications.

The companies have partnered with the goal of streamlining point-of-care access to Guardant's genomic cancer test portfolio.

The acquisition was opposed by some Quanterix shareholders. In May, Akoya also said it received an unsolicited acquisition bid for the firm.

NEW YORK – A Delaware-based physician has been accused of filing more than 100 false claims to Medicare for unnecessary genetic cancer screening tests. The US Attorney's Office for the District of ...

Investigators compared risk prediction using PathomIQ's platform to molecular test results, evaluating its ability to predict biochemical recurrence in high-risk patients.

The firms will distribute NowDx's First to Know test to more than 15 organizations nationwide, including LGBTQ+ health centers, HIV/AIDS care providers, and safety-net clinics.

NEW YORK – In vitro diagnostic firm Leinco Technologies announced Monday that it has acquired BioClin's proprietary antibody clones used as IVD raw materials, expanding Leinco's portfolio of reagents ...

The test is covered for serial use in patients with colorectal cancer in the adjuvant and recurrence monitoring settings over a five-year period.

The test is used for the detection of antibodies against Borrelia burgdorferi in serum from patients with signs, symptoms, and clinical history consistent with Lyme disease.

Last week, readers were most interested in a story about Diasorin's submission to the FDA for its POC testing instrument.